Predictive oncology inc. (AIPT)
Income statement / TTM
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenue

1,411

1,375

1,182

1,255

1,411

1,320

1,143

891

654

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of goods sold

531

506

381

372

415

369

315

228

148

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

500

451

599

654

636

948

1,032

951

844

554

387

468

499

442

316

188

173

141

119

96

22

0

0

0

-

Cost of goods sold

-

-

-

-

-

-

-

-

-

-

-

-

-

253

247

293

303

320

435

450

385

293

184

153

189

203

247

182

128

128

69

69

56

12

0

0

0

-

Gross margin

879

868

801

883

995

950

827

662

506

453

438

402

274

246

204

306

350

316

512

582

566

551

370

234

278

295

195

134

60

44

72

49

40

9

0

0

0

0

General and administrative expense

9,781

9,318

7,463

4,882

4,626

2,815

2,675

4,160

4,050

4,459

4,570

4,618

5,174

6,493

6,621

5,215

3,399

3,225

3,101

3,575

4,882

5,805

8,263

7,821

7,530

6,222

5,545

6,608

6,285

7,581

5,492

3,814

3,561

1,395

1,405

0

0

0

Operations expense

2,960

2,915

2,932

2,040

1,861

2,229

1,698

1,501

1,414

805

905

968

1,158

1,399

1,309

1,215

846

608

588

728

972

1,073

1,243

1,157

1,096

1,005

952

896

761

468

302

329

351

458

367

0

0

0

Sales and marketing expense

1,912

2,317

2,503

2,372

2,369

2,140

1,821

1,498

1,095

799

635

506

467

413

342

378

503

768

1,027

1,207

1,178

1,046

885

675

578

480

329

249

172

158

205

244

232

185

192

0

0

0

Total operating loss

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on revaluation of cash advances to Helomics

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other Expense

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating loss

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income

-

0

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other expense

-

0

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-3

48

237

390

607

687

513

377

140

416

527

636

751

367

330

259

221

259

227

230

210

209

0

0

0

Loss (gain) on valuation of equity-linked financial instruments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11

-34

30

99

157

122

75

65

-3

-286

-282

-155

-151

562

1,103

0

0

0

Total Expense

-

-

-

-

-

-

-

-

-

6,064

6,112

6,093

6,800

8,302

8,321

7,047

5,140

4,177

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on equity method investment

-439

-1,085

-2,045

0

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on revaluation of equity method investment

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deemed dividend on Series E Convertible Preferred Stock

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total Expense

-

-

-

-

-

-

-

-

-

6,388

7,882

0

-

0

0

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,778

10,081

9,684

8,338

7,119

8,019

7,482

8,716

6,542

4,772

4,527

1,687

1,070

0

0

0

Net loss attributable to common shareholders

-19,680

-9,428

-7,801

-11,619

-10,086

-7,765

-6,250

-6,421

-6,003

-5,610

-5,673

-5,691

-6,526

-8,056

-8,117

-6,741

-4,790

-4,892

-4,891

-5,442

-6,833

-7,548

-10,408

-9,847

-9,406

-8,043

-6,924

-7,884

-7,422

-8,672

-6,470

-4,722

-4,486

-1,677

-1,070

0

0

0

Gain/(loss) per common share - basic (in dollars per share)

-

-

0.05

-

-

-

-0.20

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain/(loss) per common share – diluted (in dollars per share)

-

-

0.02

-

-

-

-0.20

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average shares used in computation - basic (in shares)

-

-

29,609

-

-

-

11,878

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average shares used in computation - diluted (in shares)

-

-

60,070

-

-

-

11,878

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized gain from marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-

-

-

-

-

-

-

-

-

-5,613

-5,678

-5,692

-6,524

0

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss per common share - basic and diluted (in dollars per share)

-

-1.31

-

-0.21

-

-1.89

-

-0.15

-0.16

-0.16

-0.41

-0.21

1.97

-0.32

-0.95

-3.01

-23.34

-7.09

-0.36

-0.07

-55.63

-0.37

-0.58

-0.55

-2.44

-2.18

-0.01

-0.01

-0.01

-0.04

-0.04

-0.02

-0.11

-0.02

-0.02

-0.03

-0.01

0.00

Weighted average shares used in computation - basic and diluted (in shares)

-

3,146

-

15,731

-

1,325

-

11,383

6,600

6,232

6,167

6,450

4,554

3,320

2,695

723

-5,900

157

3,263

3,100

-8,423

2,984

2,968

2,949

-236,251

1,821

121,267

121,267

111,562

79,467

54,656

32,664

-

27,236

22,669

-

-

-

Weighted average shares used in computation - basic and diluted (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

16,557

13,159

12,353